Slideshow
Author(s):
New technology may help patients and providers assess changes in severity of Parkinson disease symptoms more objectively.
European Commission Grants NLX-112 Orphan Medicinal Product Designation for Spinocerebellar Ataxia
Episode 119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
NeurologyLive® Friday 5 — October 4, 2024
Episode 116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas
NORAPS Phase 2 Trial to Test Noradrenaline Reuptake Inhibitor Atomoxetine in PSP Apathy and Impulsivity
Continued Progress in Phase 1 Study of Antisense Oligonucleotide ION464 in MSA